IN2014DN08969A - - Google Patents
Info
- Publication number
- IN2014DN08969A IN2014DN08969A IN8969DEN2014A IN2014DN08969A IN 2014DN08969 A IN2014DN08969 A IN 2014DN08969A IN 8969DEN2014 A IN8969DEN2014 A IN 8969DEN2014A IN 2014DN08969 A IN2014DN08969 A IN 2014DN08969A
- Authority
- IN
- India
- Prior art keywords
- hypophosphatemic rickets
- pyrimid
- hyp
- piperazin
- phenylamino
- Prior art date
Links
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 abstract 2
- 208000005050 Familial Hypophosphatemic Rickets Diseases 0.000 abstract 2
- 208000031878 X-linked hypophosphatemia Diseases 0.000 abstract 2
- 208000035724 X-linked hypophosphatemic rickets Diseases 0.000 abstract 2
- 201000003674 autosomal dominant hypophosphatemic rickets Diseases 0.000 abstract 2
- 201000003672 autosomal recessive hypophosphatemic rickets Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000028060 Albright disease Diseases 0.000 abstract 1
- 208000031213 Epidermal nevus syndrome Diseases 0.000 abstract 1
- 208000029663 Hypophosphatemia Diseases 0.000 abstract 1
- 201000001853 McCune-Albright syndrome Diseases 0.000 abstract 1
- 208000005072 Oncogenic osteomalacia Diseases 0.000 abstract 1
- 208000020037 osteoglophonic dysplasia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617889P | 2012-03-30 | 2012-03-30 | |
| PCT/EP2013/056811 WO2013144339A1 (en) | 2012-03-30 | 2013-03-29 | Fgfr inhibitor for use in the treatment of hypophosphatemic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08969A true IN2014DN08969A (https=) | 2015-05-22 |
Family
ID=47998482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8969DEN2014 IN2014DN08969A (https=) | 2012-03-30 | 2013-03-29 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20150072019A1 (https=) |
| EP (1) | EP2830626B1 (https=) |
| JP (1) | JP6190871B2 (https=) |
| KR (1) | KR102126092B1 (https=) |
| CN (2) | CN109718239B (https=) |
| AU (1) | AU2013241664B2 (https=) |
| CA (1) | CA2866229C (https=) |
| IN (1) | IN2014DN08969A (https=) |
| MX (1) | MX354783B (https=) |
| RU (1) | RU2643326C2 (https=) |
| WO (1) | WO2013144339A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| EA028614B1 (ru) * | 2014-05-22 | 2017-12-29 | Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" | Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| WO2016189472A1 (en) * | 2015-05-28 | 2016-12-01 | Novartis Ag | Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor |
| BR112018001053A2 (pt) | 2015-07-20 | 2018-09-11 | Univ Taipei Medical | compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo |
| BR112018001438A2 (en) * | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | gffr expression and susceptibility to a gffr inhibitor |
| EP3566705B1 (en) | 2017-01-06 | 2022-11-23 | Lemonex Inc. | Composition for preventing or treating metastatic ovarian cancer, endometrial cancer or breast cancer |
| WO2018128510A1 (ko) * | 2017-01-06 | 2018-07-12 | 주식회사 레모넥스 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| US10886468B2 (en) | 2017-04-14 | 2021-01-05 | Sakai Display Products Corporation | Manufacturing method and manufacturing apparatus for organic EL display device |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021119108A1 (en) * | 2019-12-09 | 2021-06-17 | Cedars-Sinai Medical Center | Use of fgfr inhibitors for treatment of idiopathic short stature |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2002052009A1 (ja) * | 2000-12-26 | 2004-04-30 | 中外製薬株式会社 | 血中リン濃度を低下させるヒトｆｇｆ２３タンパク質変異体 |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1882475A1 (en) * | 2006-07-26 | 2008-01-30 | Novartis AG | Method of treating disorders mediated by the fibroblast growth factor receptor |
| CA2720888A1 (en) * | 2008-04-29 | 2009-11-05 | Novartis Ag | Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods |
| CN102596916B (zh) * | 2009-10-30 | 2015-06-17 | 诺瓦提斯公司 | 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物 |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| US20120258940A1 (en) * | 2009-12-18 | 2012-10-11 | Giordano Caponigro | Method for treating haematological cancers |
| WO2013088191A1 (en) | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
-
2013
- 2013-03-29 US US14/388,978 patent/US20150072019A1/en not_active Abandoned
- 2013-03-29 MX MX2014011841A patent/MX354783B/es active IP Right Grant
- 2013-03-29 RU RU2014143517A patent/RU2643326C2/ru active
- 2013-03-29 IN IN8969DEN2014 patent/IN2014DN08969A/en unknown
- 2013-03-29 KR KR1020147026889A patent/KR102126092B1/ko active Active
- 2013-03-29 CN CN201811194059.3A patent/CN109718239B/zh active Active
- 2013-03-29 EP EP13712589.4A patent/EP2830626B1/en active Active
- 2013-03-29 CN CN201380015597.0A patent/CN104321058A/zh active Pending
- 2013-03-29 CA CA2866229A patent/CA2866229C/en active Active
- 2013-03-29 WO PCT/EP2013/056811 patent/WO2013144339A1/en not_active Ceased
- 2013-03-29 JP JP2015502373A patent/JP6190871B2/ja active Active
- 2013-03-29 AU AU2013241664A patent/AU2013241664B2/en active Active
-
2016
- 2016-09-22 US US15/272,633 patent/US10028955B2/en active Active
-
2018
- 2018-06-12 US US16/005,966 patent/US20210308132A1/en not_active Abandoned
-
2024
- 2024-01-09 US US18/407,729 patent/US20240398798A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240398798A1 (en) | 2024-12-05 |
| US20170007606A1 (en) | 2017-01-12 |
| RU2014143517A (ru) | 2016-05-27 |
| US10028955B2 (en) | 2018-07-24 |
| EP2830626B1 (en) | 2019-01-02 |
| EP2830626A1 (en) | 2015-02-04 |
| CA2866229C (en) | 2020-09-15 |
| JP6190871B2 (ja) | 2017-08-30 |
| KR20140145133A (ko) | 2014-12-22 |
| RU2643326C2 (ru) | 2018-01-31 |
| MX354783B (es) | 2018-03-21 |
| CN104321058A (zh) | 2015-01-28 |
| KR102126092B1 (ko) | 2020-06-24 |
| CN109718239B (zh) | 2024-09-10 |
| US20210308132A1 (en) | 2021-10-07 |
| CN109718239A (zh) | 2019-05-07 |
| MX2014011841A (es) | 2015-02-10 |
| US20150072019A1 (en) | 2015-03-12 |
| JP2015511621A (ja) | 2015-04-20 |
| CA2866229A1 (en) | 2013-10-03 |
| WO2013144339A1 (en) | 2013-10-03 |
| AU2013241664B2 (en) | 2016-05-19 |
| AU2013241664A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08969A (https=) | ||
| TN2012000263A1 (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof. | |
| PH12014501979A1 (en) | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor | |
| MY172021A (en) | Rsv antiviral compounds | |
| MY180383A (en) | Cortistatin analogues and syntheses and uses thereof | |
| CY1124329T1 (el) | N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων | |
| EA030383B9 (ru) | Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением | |
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| PH12016502523A1 (en) | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| MX2012002544A (es) | Pteridinas y sus usos como agroquimicos. | |
| PH12014501937A1 (en) | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative | |
| GEAP201914215A (en) | Pharmaceutical composition containing pyridylamino acetic acid compound | |
| CO6270323A2 (es) | Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro- 1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico y metodos para su uso | |
| TW201613561A (en) | Composition comprising reduced coenzyme q10 | |
| UY34223A (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas | |
| CL2011002278A1 (es) | Proceso para la preparacion de (e)-n-(4-(3-ter-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-2-metoxiestiril)fenil)metansulfonamida o su sal por reduccion del correspondiente etinilo; y los compuestos intermediarios considerados. | |
| UA112423C2 (uk) | Спосіб одержання (варіанти) кристалічних форм розувастатину тба | |
| MX2017008430A (es) | Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. | |
| PH12015500322B1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| AU2012307449A8 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
| MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
| MX2010011006A (es) | Nueva sal de un derivado de pirimidina. | |
| GB201004677D0 (en) | New salt | |
| AR080363A1 (es) | Cristal molecular de derivado de (4-(1,8-naftiridin -2-il) piperidin-1-il) pirimidina | |
| CA2863110A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators |